Shares of Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) have received a consensus rating of “Hold” from the eight research firms that are presently covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and five have given a buy recommendation to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $26.20.

BLCM has been the subject of several analyst reports. BidaskClub upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, August 25th. Raymond James Financial, Inc. restated a “buy” rating on shares of Bellicum Pharmaceuticals in a research note on Tuesday, June 27th. Cantor Fitzgerald restated an “overweight” rating and issued a $35.00 target price on shares of Bellicum Pharmaceuticals in a research note on Monday, June 26th. ValuEngine downgraded Bellicum Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Friday, August 11th. Finally, Jefferies Group LLC restated a “buy” rating and issued a $16.00 target price (down previously from $18.00) on shares of Bellicum Pharmaceuticals in a research note on Thursday, August 10th.

ILLEGAL ACTIVITY WARNING: “Bellicum Pharmaceuticals, Inc. (BLCM) Receives Consensus Rating of “Hold” from Brokerages” was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The correct version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/09/bellicum-pharmaceuticals-inc-blcm-receives-consensus-rating-of-hold-from-brokerages.html.

In related news, VP Ken Moseley sold 13,823 shares of the firm’s stock in a transaction dated Thursday, July 13th. The stock was sold at an average price of $12.26, for a total transaction of $169,469.98. Following the transaction, the vice president now directly owns 14,314 shares of the company’s stock, valued at approximately $175,489.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider David M. Spencer sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 10th. The shares were sold at an average price of $11.54, for a total value of $115,400.00. The disclosure for this sale can be found here. Over the last three months, insiders have sold 24,260 shares of company stock worth $290,048. 23.30% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in BLCM. Foresite Capital Management III LLC purchased a new position in shares of Bellicum Pharmaceuticals during the 1st quarter valued at about $11,328,000. LMR Partners LLP purchased a new position in shares of Bellicum Pharmaceuticals during the 1st quarter valued at about $3,339,000. JPMorgan Chase & Co. raised its holdings in shares of Bellicum Pharmaceuticals by 10.2% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,466,752 shares of the biopharmaceutical company’s stock valued at $28,811,000 after buying an additional 227,668 shares in the last quarter. Sphera Funds Management LTD. purchased a new position in shares of Bellicum Pharmaceuticals during the 1st quarter valued at about $2,468,000. Finally, Vanguard Group Inc. raised its holdings in shares of Bellicum Pharmaceuticals by 17.8% during the 1st quarter. Vanguard Group Inc. now owns 1,061,582 shares of the biopharmaceutical company’s stock valued at $13,100,000 after buying an additional 160,151 shares in the last quarter. 55.73% of the stock is currently owned by institutional investors.

Shares of Bellicum Pharmaceuticals (NASDAQ BLCM) opened at 10.04 on Friday. Bellicum Pharmaceuticals has a 12 month low of $7.41 and a 12 month high of $23.11. The company’s market cap is $333.59 million. The stock has a 50 day moving average of $9.68 and a 200-day moving average of $11.78.

Bellicum Pharmaceuticals (NASDAQ:BLCM) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.65) by $0.09. Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same period in the prior year, the company posted ($0.61) earnings per share. Equities analysts forecast that Bellicum Pharmaceuticals will post ($3.02) earnings per share for the current year.

Bellicum Pharmaceuticals Company Profile

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Analyst Recommendations for Bellicum Pharmaceuticals (NASDAQ:BLCM)

Receive News & Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.